Erasca, Inc. (ERAS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Diego, CA, United States. El CEO actual es Jonathan E. Lim.
ERAS tiene fecha de IPO 2021-07-16, 103 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $5.55B.
Erasca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapies for cancers driven by RAS/MAPK pathway alterations. The company's lead program, ERAS-007, is an oral ERK1/2 inhibitor in development for non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia, while ERAS-601, an oral SHP2 inhibitor, targets advanced and metastatic solid tumors. Erasca is also advancing ERAS-801, a CNS-penetrant EGFR inhibitor designed to treat recurrent glioblastoma multiforme. Founded in 2018 and headquartered in San Diego, California, the company aims to address significant unmet needs in oncology through precision-targeted drug development.
